← All candidates
One insider bought $10.73M in five days.
64 filings on record.
ALMSALUMIS INC.
NasdaqGS · Healthcare · $1.03B
$7.94
-5.48% · Sep 16
One insider bought $10.73M in five days.
Led by Akkaraju Srinivas, director.
Price · 1Y · daily● 40 buys● 9 sells◆ 7 8-K
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$1.03B
Float
97.2M
75% public
Short % float
Pro
Price / profit
—
not yet profitable
Price / future profit
—
Price / sales
138.9
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
Director
Akkaraju Srinivas
Bought $10.00M on Jan 9 — 588,235 sh @ $17.00, held indirect, 32% of their stake.
2 of 4 positions beat the S&P
10% owner
Foresite Labs, LLC
Bought $5.00M on Jan 8 — 294,117 sh @ $17.00, held indirect, 10% of their stake.
1 of 1 position beat the S&P
10% owner
Foresite Capital Management VI LLC
Bought $5.00M on Jan 8 — 294,117 sh @ $17.00, held indirect, 10% of their stake.
1 of 1 position beat the S&P
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
2 filingsnewest first
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
59 more transactions on Pro →Context
Wall St
$32.13 avg target
+304.6% vs today · 8 analysts · consensus Strong Buy
▸ relayed analyst opinion, which tends to run optimistic — not our forecast or advice
Earnings · EPS vs forecast
2 of 5 quarters beat
Q2 '26−$0.79 act−$0.08
Q1 '26−$0.74 act+$0.09
Q4 '25−$0.25 act+$0.72
Q3 '25−$1.06 act−$0.06
Coverage
Stifel and Guggenheim Stay Bullish on Alumis (ALMS)Insider Monkey · 07-01Analyst Sentiment On Alumis (ALMS) Remains Strong Following Q1 Results And Envudeucitinib Pipeline AdvancementsInsider Monkey · 05-29Is Alumis (ALMS) Trading Short-Term Revenue for a Leaner, More Focused Business Model?Simply Wall St. · 05-20Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last QuarterMotley Fool · 05-17
The file stays open
64 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice